Zymeworks Enters Global License and Collaboration Agreement With Roche for ZW209
Zymeworks announced an exclusive global license and collaboration agreement with Roche for ZW209, a trispecific T-cell engager targeting DLL3.
Story updates
10:03:55 AM UTC
SquawkNews
Zymeworks signed a global license with Roche for ZW209, with $55M upfront, $40M at Phase 1b start, and up to $718M in milestones plus tiered royalties. Deal is subject to HSR and other customary approvals; Roche will lead global development and commercialization.Material DetailsContext by AI Analys…
VANCOUVER, British Columbia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. NASDAQ:ZYME, a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that it has entered into a global lice…